J. Stern & Co. LLP Has $1.80 Billion Stock Position in IDEXX Laboratories, Inc. $IDXX

J. Stern & Co. LLP raised its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 23,694.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,653,351 shares of the company’s stock after acquiring an additional 2,642,200 shares during the period. IDEXX Laboratories comprises approximately 0.5% of J. Stern & Co. LLP’s holdings, making the stock its 24th largest holding. J. Stern & Co. LLP’s holdings in IDEXX Laboratories were worth $1,795,072,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Virtus Advisers LLC acquired a new position in IDEXX Laboratories in the 3rd quarter valued at approximately $26,000. Park Place Capital Corp acquired a new position in IDEXX Laboratories in the 4th quarter valued at approximately $29,000. Mowery & Schoenfeld Wealth Management LLC raised its holdings in IDEXX Laboratories by 58.8% in the 4th quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock valued at $37,000 after acquiring an additional 20 shares in the last quarter. Wormser Freres Gestion raised its holdings in IDEXX Laboratories by 671.4% in the 4th quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock valued at $37,000 after acquiring an additional 47 shares in the last quarter. Finally, WealthCollab LLC acquired a new position in IDEXX Laboratories in the 2nd quarter valued at approximately $30,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Stock Up 0.5%

NASDAQ IDXX opened at $573.00 on Wednesday. The firm has a market cap of $45.20 billion, a PE ratio of 42.19, a price-to-earnings-growth ratio of 3.12 and a beta of 1.55. IDEXX Laboratories, Inc. has a one year low of $506.91 and a one year high of $769.98. The stock’s 50 day simple moving average is $563.14 and its 200 day simple moving average is $624.14. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.IDEXX Laboratories’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same period in the prior year, the company earned $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on IDXX. Citigroup began coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price target for the company. Stifel Nicolaus cut their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Wall Street Zen raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Saturday. Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Finally, UBS Group lowered their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Seven analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.